40 results on '"Rossi, A.B."'
Search Results
2. Laboratory safety from a 16-week, phase 3 study of dupilumab in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis
3. Efficacy and safety of dupilumab treatment with concomitant topical corticosteroids in children aged 6 months to 5 years with severe atopic dermatitis
4. Dupilumab demonstrates improvements in biomarker levels across racial subgroups in pediatric patients with moderate-to-severe atopic dermatitis
5. Dupilumab treatment results in rapid, sustained and clinically meaningful improvement in itch in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis
6. Dupilumab treatment in children aged 6–11 years with severe atopic dermatitis is associated with reductions in serum immunoglobulin E and thymus and activation-regulated chemokine levels
7. Efficacy of a global supportive skin care programme with hydrotherapy after non‐metastatic breast cancer treatment: A randomised, controlled study
8. Type 2 inflammation contributes to skin barrier dysfunction in atopic dermatitis
9. 273 Dupilumab treatment-associated reduction in total IgE levels correlates with flare probability reduction in patients with moderate and severe atopic dermatitis
10. Fragility of epidermis: acne and post‐procedure lesional skin
11. IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis*
12. Dupilumab significantly modulates pain and discomfort in patients with atopic dermatitis : a post hoc analysis of 5 randomized clinical trials
13. 397 Dupilumab improves health-related quality of life (HRQoL) in children aged ≥6–<12 years with severe atopic dermatitis (AD)
14. Le dupilumab améliore les signes et symptômes de dermatite atopique érythrodermique chez des patients adultes et adolescents – analyse poolée de sous-groupes
15. 382 Dupilumab treatment provides continued improvements in signs and symptoms through week 100 in patients with moderate-to-severe atopic dermatitis who did not achieve ≥75% reduction in eczema area and severity index at week 16
16. 409 Dupilumab prevents flares in adults with moderate-to-severe atopic dermatitis in a 52-week, randomized, controlled, phase 3 trial
17. 455 Dupilumab monotherapy improves signs, symptoms and quality of life in adult and adolescent patients with erythrodermic atopic dermatitis
18. 408 Long-term treatment with dupilumab minimizes use of systemic immunosuppressants as rescue medications in adults with moderate-to-severe atopic dermatitis
19. 评估接受 Dupilumab 治疗的中度至重度特应性皮炎患者进行常规安全性检测的必要性
20. Assessing the need for routine safety testing for patients being treated with dupilumab for moderate‐to‐severe atopic dermatitis
21. Response to R. Waldman et al .: ‘Does IL‐4 inhibition play a role in dupilumab‐associated conjunctivitis?’
22. Effets à long terme du dupilumab sur les valeurs du SCORAD dans l’évaluation de la dermatite atopique modérée à sévère : résultats de l’étude de phase 3 LIBERTY AD CHRONOS
23. Efficacité et sécurité du dupilumab chez des patients adultes atteints de dermatite atopique modérée à sévère ayant des antécédents d’utilisation d’immunosuppresseur : analyse post-hoc de l’étude de phase 3 CAFÉ
24. Effets du dupilumab sur les résultats du SCORAD dans la dermatite atopique modérée à sévère : résultats de l’étude de phase 3 LIBERTY AD CAFÉ
25. Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)
26. 101 Dupilumab Improves Outcomes of Concurrent Asthma and Chronic Sino-Nasal Conditions in Patients With Atopic Dermatitis—a Pooled Analysis of Four Phase 3 Studies (LIBERTY AD SOLO 1 & 2, CHRONOS, and CAFÉ)
27. 178 Effect of Dupilumab on Global Individual Signs Score Outcomes in Adults With Moderate-to-Severe Atopic Dermatitis: Combined Results From Four Phase 3 Trials
28. Stepwise approach of development of dermo‐cosmetic products in healthy and atopic dermatitis paediatric population: safety evaluation, clinical development and postmarket surveillance
29. 621 Dupilumab in adolescents with moderate-to-severe atopic dermatitis and a history of inadequate response, or intolerance to cyclosporine: subgroup analysis from a pivotal 16-week trial
30. 615 Dupilumab elicits rapid and sustained improvements in itch in adults with moderate-to-severe atopic dermatitis
31. Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials
32. Improvement of atopic dermatitis with dupilumab occurs equally well across different anatomical regions: data from phase III clinical trials
33. Laboratory safety of dupilumab in moderate‐to‐severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
34. Efficacy of a global supportive skin care programme with hydrotherapy after non-metastatic breast cancer treatment: A randomised, controlled study
35. 051 Assessment of the anti-aging protection of the association of Retinaldehyde, Hyaluronic acid mono-oligomers and Ascofilline abc™ in elderly patients
36. Fragility of epidermis in newborns, children and adolescents
37. Évaluation de la tolérance cutanée d’une crème réparatrice après laser ou peeling superficiel
38. Optimization of Regulated LTR-Mediated Expression
39. Retroviral Delivery of Peptide Modulators of Cellular Functions
40. Quantitative measurement of mast cell degranulation using a novel flow cytometric annexin-V binding assay
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.